Replimune Group (REPL)
NASDAQ:REPL
Want to see REPL full AI Analyst Report?
REPL Stock Chart & Stats
$2.17
$0.17(1.56%)
At close: 4:00 PM EST
$2.17
$0.17(1.56%)
Day’s Range― - ―
52-Week Range$1.50 - $13.24
Previous CloseN/A
Volume95.41K
Average Volume (3M)5.93M
Market Cap
$250.20M
Enterprise Value$203.59M
Total Cash (Recent Filing)$269.14M
Total Debt (Recent Filing)$76.35M
Price to Earnings (P/E)―
Beta>-0.01
Next Earnings
May 14, 2026EPS Estimate
-0.65Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.58
Shares Outstanding82,572,620
10 Day Avg. Volume14,545,134
30 Day Avg. Volume5,927,637
Financial Highlights & Ratios
PEG Ratio0.61
Price to Book (P/B)1.89
Price to Sales (P/S)0.00
P/FCF Ratio-3.95
Enterprise Value/Market Cap0.81
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-240.08
Enterprise Value/Ebitda-0.65
Forecast
1Y Price Target
$2.25Price Target Upside3.69% Upside
Rating ConsensusModerate Sell
Number of Analyst Covering7
EPS Forecast (FY)-1.63
Revenue Forecast (FY)$43.62M
Bulls Say, Bears Say
Bulls Say
Clinical DataAnalyst assesses the totality of RP1 clinical data in advanced melanoma as compelling, supporting meaningful commercial potential in an area of high unmet medical need.
Commercial FundingAnalyst notes the company holds sufficient cash to fund initial commercial activities for RP1, reducing immediate financing risk if approval is achieved.
Regulatory Staffing ChangeAnalyst views the departure of a key FDA reviewer as an incremental positive that could improve the probability of approval for RP1.
Bears Say
Financing And Operational RiskAnalyst warns the company may require substantial external financing and strategic restructuring, which could lead to workforce reductions and pressure the stock as resources shift to a pivotal trial.
Regulatory SetbackAnalyst cites the FDA's complete response letter for RP1 plus nivolumab as a major regulatory setback that extends the timeline and increases uncertainty for approval.
Trial Design WeaknessesAnalyst highlights fundamental trial design concerns—reliance on single-arm data, patient heterogeneity, and inability to isolate RP1's contribution—that undermine confidence in the evidence package.
Replimune Group News
REPL FAQ
What was Replimune Group’s price range in the past 12 months?
Replimune Group lowest stock price was $1.50 and its highest was $13.24 in the past 12 months.
What is Replimune Group’s market cap?
Replimune Group’s market cap is $250.20M.
When is Replimune Group’s upcoming earnings report date?
Replimune Group’s upcoming earnings report date is May 14, 2026 which is in 9 days.
How were Replimune Group’s earnings last quarter?
Replimune Group released its earnings results on Feb 03, 2026. The company reported -$0.77 earnings per share for the quarter, missing the consensus estimate of -$0.763 by -$0.007.
Is Replimune Group overvalued?
According to Wall Street analysts Replimune Group’s price is currently Undervalued.
Does Replimune Group pay dividends?
Replimune Group does not currently pay dividends.
What is Replimune Group’s EPS estimate?
Replimune Group’s EPS estimate is -0.65.
How many shares outstanding does Replimune Group have?
Replimune Group has 82,572,620 shares outstanding.
What happened to Replimune Group’s price movement after its last earnings report?
Replimune Group reported an EPS of -$0.77 in its last earnings report, missing expectations of -$0.763. Following the earnings report the stock price went up 5.806%.
Which hedge fund is a major shareholder of Replimune Group?
Currently, no hedge funds are holding shares in REPL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Replimune Group Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Sell
Average Price Target:
$2.25 (3.69% Upside)
$2.25 (3.69% Upside)
Blogger Sentiment
Bullish
REPL Sentiment 70%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 315.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 0.8%
Last 30 Days ▲ 7.9%
Last 30 Days ▲ 7.9%
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-72.85%
12-Months-Change
Fundamentals
Return on Equity
-102.69%
Trailing 12-Months
Asset Growth
-44.74%
Trailing 12-Months
Company Description
Replimune Group
Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1, which is in Phase I/II clinical trials for a range of solid tumors; and that is in Phase II clinical trials for patients with cutaneous squamous cell carcinoma. It is also developing RP2, which is in Phase I clinical trials for an anti-CTLA-4 antibody-like protein in order to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trials to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.
REPL Stock 12 Month Forecast
Average Price Target
$2.25
▲(3.69% Upside)
Technical Analysis
Anavex Life Sciences
―
Arcus Biosciences
―
Oric Pharmaceuticals
―
Nurix Therapeutics
―
Sana Biotechnology
―
Ownership Overview
3.67% Insiders
17.69% Mutual Funds
0.81% Other Institutional Investors
64.72% Public Companies and
Individual Investors